2026-06-14T03:39:41Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/158802025-05-05T10:08:49Zcom_20.500.12105_2052com_20.500.12105_2051col_20.500.12105_19616

00925njm 22002777a 4500 dc Martín-Carrasco, Clara author Delgado-Bonet, Pablo author Tomeo-Martín, Beatriz Davinia author Pastor, Josep author de la Riva, Claudia author Palau-Concejo, Paula author Del Castillo, Noemí author Garcia-Castro, Javier author Perise-Barrios, Ana Judith author 2022-06-28 The use of oncolytic viruses is an innovative approach to lyse tumor cells and induce antitumor immune responses. Eight dogs diagnosed with carcinoma/adenocarcinoma were intratumorally treated with ICOCAV15, an oncolytic canine adenovirus (CAV). To evaluate the treatment's safety, a blood count, biochemistry, and coagulation test were performed before treatment and during follow-up. Immune populations were analyzed by flow cytometry. Anti-adenovirus antibodies were also determined. The immune infiltration, vascularization, and viral presence in the tumor were determined by CD3, CD4, CD20, CD31 and CAV by immunohistochemistry. All the dogs maintained a good quality of life during follow-up, and some had increased median survival time when compared with dogs treated with chemotherapy. No treatment-related adverse effects were detected. The Response Evaluation Criteria In Solid Tumors criteria were also assessed: two patients showed a partial response and the rest showed stable disease at various times during the study. ICOCAV15 was detected inside the tumor during follow-up, and antiviral antibodies were detected in all patients. Furthermore, the tumor-infiltrating immune cells increased after viral administration. Therefore, we suggest that intratumorally administered ICOCAV15 could represent as a new tool for the treatment of canine carcinoma because it is safe, well-tolerated by dogs, and shows promising results. Vet Sci. 2022 Jun 28;9(7):327. 10.3390/vetsci9070327 2306-7381 Veterinary sciences 35878344 http://hdl.handle.net/20.500.12105/15880 Oncolytic Viruses Virotherapy Immunotherapy ICOCAV15 Canine carcinoma Safety and Efficacy of an Oncolytic Adenovirus as an Immunotherapy for Canine Cancer Patients